Thursday, April 10, 2014

Alzheimer's Clinical Trials

Alzheimer’s disease is the most common dementia affecting millions of Americans.  It impacts many of our clients as well.  Those suffering with it now are using a number of medications, most of which have been in use for several years.  There is a need for new medical treatments to manage and hopefully someday eliminate this disease.  The process of developing these new medications can take years of research and clinical trials.  Visiting Angels is pleased to announce we are giving referrals for clinical trials for investigational medications to treat Alzheimer’s disease in association with Donald S. Marks, MD, a Board Certified Neurologist, specialist in Alzheimer’s disease and an Assistant Clinical Professor at Tufts. 

We are currently seeking participants for a very important study.  Enrollment in this Phase 3 clinical trial is in progress.  By participating in the clinical trial, participants will be part of an effort that may help them improve their mental function. In addition,  participants will provide valuable data that may help others in the future.

To be eligible to participate in the study participants should have a diagnosis of mild to moderate Alzheimer’s disease, have previously been on or are currently on a stable dose of Aricept (donepezil), Exelon (rivastigmine), or Razadyne (Galantamine) and be between the ages of 55 and 85.  Participants who are taking Namenda (memantine) are not appropriate for the study. 

If you or the person you care for would like to participate in this clinical trial please contact Nate Murray at 781-834-6355 extension 12.  He can give you further information and begin the process of coordinating your introduction to Dr. Marks.